The title "Father of Modern Gynecology" is often attributed to Dr James Marion Sims, a pioneering American physician whose contributions to gynecology have profoundly influenced modern medical practice. Born in 1813, Sims developed several innovative surgical techniques and instruments that revolutionized the treatment of gynecological conditions. Among his most notable contributions is the Sims speculum, which remains a fundamental tool in gynecological examinations today. Sims is also credited with pioneering surgical techniques for repairing VVFs, previously deemed untreatable. His work, primarily conducted in the mid-19th century, laid the foundation for modern gynecological surgery and significantly advanced women's healthcare. However, Sims' legacy is also marked by ethical controversy. His early research involved experimental surgeries on enslaved African-American women, conducted without the use of anesthesia. These practices have sparked critical discussions regarding medical ethics, informed consent, and the historical exploitation of marginalized groups under the guise of scientific progress. This review article explores the dual facets of James Marion Sims' legacy, acknowledging his crucial role in shaping modern gynecology while critically examining the ethical implications of his methods. Such a discussion is vital for understanding the evolution of medical practices and the ongoing need for stringent ethical standards in clinical research and patient care.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11480236 | PMC |
| http://dx.doi.org/10.7759/cureus.69484 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
N Engl J Med
July 2024
From the Department of Gastroenterology, INFINY Institute, INSERM NGERE, Centre Hospitalier Régional Universitaire de Nancy, Vandœuvre-lès-Nancy, France (L.P.-B.); the Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal (L.P.-B.), and the Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB (R.P.) - both in Canada; the Crohn's and Colitis Center at the Baton Rouge General and the GI Alliance, Baton Rouge, LA (J.C.C.); the Henry D. Janowitz Division of Gastroenterology, Department of Medicine (J.-F.C.), and the Susan and Leonard Feinstein IBD Center (M.D.), Icahn School of Medicine at Mount Sinai, New York; the Department of Pathophysiology and Transplantation, Università degli Studi di Milano and the Unit of Gastroenterology and Endoscopy, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico di Milano (F.C.), and Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele (S.D.) - both in Milan; the Department of Gastroenterology, Amsterdam University Medical Centers, Amsterdam (G.D.); the Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven (M.F.), and the Imelda GI Clinical Research Center, Department of Gastroenterology, Imelda General Hospital, Bonheiden (P.B.) - both in Belgium; the Department of Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel (S.S.), the Department of Medicine 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen (R.A.), and the Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin (B.S.) - all in Germany; the Centre for Immunobiology, Barts and the London School of Medicine and Dentistry, Queen Mary University of London (J.O.L.), the Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust (P.M.I.), and the School of Immunology and Microbial Sciences, King's College London (P.M.I.) - all in London; the Department of Gastroenterology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, China (Q.C.); and AbbVie, North Chicago, IL (E.N., K.W., T.A., K.K., W.R.D., V.P., X.H., S.B., L.S.).
Article Synopsis
- A phase 3b clinical trial was conducted to compare the effectiveness and safety of risankizumab and ustekinumab in patients with moderate-to-severe Crohn's disease who didn't respond to anti-TNF therapy.
- The study evaluated two primary outcomes: clinical remission at week 24 and endoscopic remission at week 48, with risankizumab being tested for noninferiority and superiority, respectively.
- Results showed that risankizumab was not only noninferior to ustekinumab for clinical remission but also superior for endoscopic remission, with significant improvements reported in patients receiving risankizumab.
Fluorescent-protein co-expression to select CHO cells expressing high quantities of vaccine antigens.
Biotechnol J
May 2024
GSK, Rockville, Maryland, USA.
Cell line development for production of vaccine antigens or therapeutic proteins typically involves transfection, selection, and enrichment for high-expressing cells. Enrichment methods include minipool enrichment, antibody-based enrichment, and enrichment based on co-expressed fluorescent biosensor proteins. However, these methods have limitations regarding labor and cost intensity, the generation of antibodies and assurance of their viral safety, and potential expression-interference or signal-saturation of the co-expressed fluorescent protein.
View Article and Find Full Text PDFMyeloid cell influx into the colonic epithelium is associated with disease severity and non-response to anti-Tumor Necrosis Factor Therapy in patients with Ulcerative Colitis.
bioRxiv
June 2023
Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ulcerative colitis (UC) is an idiopathic chronic inflammatory disease of the colon with sharply rising global prevalence. Dysfunctional epithelial compartment (EC) dynamics are implicated in UC pathogenesis although EC-specific studies are sparse. Applying orthogonal high-dimensional EC profiling to a Primary Cohort (PC; n=222), we detail major epithelial and immune cell perturbations in active UC.
View Article and Find Full Text PDFEndoscopic submucosal dissection for colorectal dysplasia in inflammatory bowel disease: a US multicenter study.
Endosc Int Open
April 2022
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.
In patients with inflammatory bowel disease (IBD), endoscopically visible lesions with distinct borders can be considered for endoscopic resection. The role of endoscopic submucosal dissection (ESD) for these lesions is not well defined because of a paucity of data. We aimed to evaluate the outcomes of colorectal ESD of dysplastic lesions in patients with IBD across centers in the United States.
View Article and Find Full Text PDFBeyond the SCENIC route: updates in chromoendoscopy and dysplasia screening in patients with inflammatory bowel disease.
Gastrointest Endosc
January 2022
Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!